882 related articles for article (PubMed ID: 20697807)
21. Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study.
Powe DG; Voss MJ; Habashy HO; Zänker KS; Green AR; Ellis IO; Entschladen F
Breast Cancer Res Treat; 2011 Nov; 130(2):457-63. PubMed ID: 21298476
[TBL] [Abstract][Full Text] [Related]
22. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
23. Male breast cancer: immunohistochemical subtypes and clinical outcome characterization.
Sánchez-Muñoz A; Román-Jobacho A; Pérez-Villa L; Sánchez-Rovira P; Miramón J; Pérez D; Sáez MI; de Luque V; Medina L; Ramírez-Tortosa CL; Vicioso L; Medina JA; Ribelles N; Alba E
Oncology; 2012; 83(4):228-33. PubMed ID: 22907070
[TBL] [Abstract][Full Text] [Related]
24. Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis.
Thorat MA; Marchio C; Morimiya A; Savage K; Nakshatri H; Reis-Filho JS; Badve S
J Clin Pathol; 2008 Mar; 61(3):327-32. PubMed ID: 18037662
[TBL] [Abstract][Full Text] [Related]
25. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.
González LO; Corte MD; Junquera S; González-Fernández R; del Casar JM; García C; Andicoechea A; Vázquez J; Pérez-Fernández R; Vizoso FJ
Hum Pathol; 2009 Sep; 40(9):1224-33. PubMed ID: 19439346
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemically defined subtypes and outcome of apocrine breast cancer.
Dellapasqua S; Maisonneuve P; Viale G; Pruneri G; Mazzarol G; Ghisini R; Mazza M; Iorfida M; Rotmensz N; Veronesi P; Luini A; Goldhirsch A; Colleoni M
Clin Breast Cancer; 2013 Apr; 13(2):95-102. PubMed ID: 23245877
[TBL] [Abstract][Full Text] [Related]
27. Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance.
Habashy HO; Powe DG; Rakha EA; Ball G; Paish C; Gee J; Nicholson RI; Ellis IO
Eur J Cancer; 2008 Jul; 44(11):1541-51. PubMed ID: 18538561
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of geminin expression levels in Ki67-high subset of estrogen receptor-positive and HER2-negative breast cancers.
Yagi T; Inoue N; Yanai A; Murase K; Imamura M; Miyagawa Y; Enomoto Y; Nishimukai A; Takatsuka Y; Hirota S; Akazawa K; Miyoshi Y
Breast Cancer; 2016 Mar; 23(2):224-30. PubMed ID: 25082658
[TBL] [Abstract][Full Text] [Related]
29. Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance.
Karn T; Ruckhäberle E; Hanker L; Müller V; Schmidt M; Solbach C; Gätje R; Gehrmann M; Holtrich U; Kaufmann M; Rody A
Breast Cancer Res Treat; 2011 Nov; 130(2):409-20. PubMed ID: 21203899
[TBL] [Abstract][Full Text] [Related]
30. Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact.
Ibrahim T; Farolfi A; Scarpi E; Mercatali L; Medri L; Ricci M; Nanni O; Serra L; Amadori D
Oncology; 2013; 84(3):150-7. PubMed ID: 23257904
[TBL] [Abstract][Full Text] [Related]
31. FOXA1 Expression Significantly Predict Response to Chemotherapy in Estrogen Receptor-Positive Breast Cancer Patients.
Xu C; Wei Q; Guo J; Zhou JC; Mei J; Jiang ZN; Shen JG; Wang LB
Ann Surg Oncol; 2015; 22(6):2034-9. PubMed ID: 25707489
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of current prognostic and predictive markers in breast cancer: a validation study of tissue microarrays.
Batistatou A; Televantou D; Bobos M; Eleftheraki AG; Kouvaras E; Chrisafi S; Koukoulis GK; Malamou-Mitsi V; Fountzilas G
Anticancer Res; 2013 May; 33(5):2139-45. PubMed ID: 23645767
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological parameters and biological markers predicting non-sentinel node metastasis in sentinel node-positive breast cancer patients.
Kwon Y; Ro J; Kang HS; Kim SK; Hong EK; Khang SK; Gong G; Ro JY
Oncol Rep; 2011 Apr; 25(4):1063-71. PubMed ID: 21258771
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
[TBL] [Abstract][Full Text] [Related]
35. Nucleobindin 2 in human breast carcinoma as a potent prognostic factor.
Suzuki S; Takagi K; Miki Y; Onodera Y; Akahira J; Ebata A; Ishida T; Watanabe M; Sasano H; Suzuki T
Cancer Sci; 2012 Jan; 103(1):136-43. PubMed ID: 21988594
[TBL] [Abstract][Full Text] [Related]
36. Cyclin D1 overexpression associates with favourable prognostic factors in invasive breast carcinoma.
El-Hafez AA; El Aaty Shawky A; Hasan B
Cancer Biomark; 2012; 12(4):149-54. PubMed ID: 23568005
[TBL] [Abstract][Full Text] [Related]
37. The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer.
El Ansari R; Alfarsi L; Craze ML; Masisi BK; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2020 May; 181(1):1-12. PubMed ID: 32200487
[TBL] [Abstract][Full Text] [Related]
38. Novel prognostic markers for patients with triple-negative breast cancer.
Zhou L; Li K; Luo Y; Tian L; Wang M; Li C; Huang Q
Hum Pathol; 2013 Oct; 44(10):2180-7. PubMed ID: 23845466
[TBL] [Abstract][Full Text] [Related]
39. A novel morphologic-molecular recurrence predictive model refines traditional prognostic tools for invasive breast carcinoma.
Ni YB; Tsang JY; Chan SK; Tse GM
Ann Surg Oncol; 2014 Sep; 21(9):2928-33. PubMed ID: 24743910
[TBL] [Abstract][Full Text] [Related]
40. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
